Puma Biotechnology Grants Stock Awards to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy PBYI?
Source: Newsfilter
- Stock Award Program: On February 3, 2026, Puma Biotechnology approved the grant of 14,750 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Vesting Conditions: Under the 2017 Employment Inducement Incentive Award Plan, the stock units will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter, ensuring continued employee service.
- Product Development Progress: Puma focuses on developing innovative cancer treatment products, having received FDA approval for neratinib in 2017, which further solidifies its market position in breast cancer treatment.
- Clinical Trial Initiation: In 2024, Puma initiated the ALISCA™-Lung1 Phase II clinical trial for small cell lung cancer, demonstrating the company's ongoing efforts and market potential in cancer drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBYI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBYI
Wall Street analysts forecast PBYI stock price to fall
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 6.210
Low
2.00
Averages
3.50
High
5.00
Current: 6.210
Low
2.00
Averages
3.50
High
5.00
No data
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adidas Disappoints with 2026 Outlook, Shares Drop
- 2026 Profit Outlook: Adidas forecasts an operating profit of around €2.3 billion ($2.68 billion) for 2026, despite a €400 million negative impact from U.S. tariffs and unfavorable currency fluctuations, which is 15% below overall market expectations, potentially disappointing investors.
- Sales Growth Forecast: The company anticipates high single-digit revenue growth in 2026 based on 2025's total of €24.8 billion ($28.86 billion), indicating that Adidas faces significant challenges in a global sportswear market characterized by excess supply and shifting consumer preferences.
- Stock Price Volatility: Adidas shares fell as much as 8% on Wednesday morning, hitting a fresh 52-week low, and have nearly halved over the past year, reflecting ongoing investor skepticism about the company's future, particularly as it navigates turnarounds alongside competitors Puma and Nike.
- Executive Contract Extension: Adidas also announced the extension of CEO Bjørn Gulden's contract until 2030, signaling confidence in his strategic direction, as Gulden has been working to stabilize the company following its split with rapper Ye, which triggered a significant crisis for the brand.
See More
Adidas Provides Disappointing 2026 Outlook Amidst Challenges
- 2026 Revenue Outlook: Adidas anticipates revenue growth in the high single digits for 2026 from 2025's €24.8 billion ($28.86 billion), despite facing challenges from U.S. tariffs and unfavorable currency fluctuations, indicating vulnerability in a deteriorating market environment.
- Operating Profit Forecast: The company expects operating profit to reach around €2.3 billion, yet a €400 million negative impact from U.S. tariffs results in a profitability outlook that is 15% below market expectations, potentially leading to investor dissatisfaction and declining confidence.
- Sales and Profit Performance: Fourth-quarter sales were €6.1 billion, with profit at €164 million, both slightly missing FactSet estimates, demonstrating that Adidas's growth remains challenged amid external turbulence, which could affect future market performance.
- CEO Contract Extension: Adidas announced the extension of CEO Bjørn Gulden's contract until 2030, reflecting confidence in his strategy, particularly after the split with Ye, as Gulden's leadership is seen as crucial for stabilizing the company.
See More
European Markets Set for Muted Open Ahead of Earnings Reports
- Market Opening Expectations: The London FTSE 100 is projected to open 0.3% higher according to IG data, while Germany's DAX and France's CAC 40 are expected to open nearly flat, indicating a cautious sentiment among investors ahead of upcoming earnings reports and economic data.
- Earnings Reporting Day: On Friday, several European companies including BASF, Swiss Re, Holcim, IAG, and Amadeus are set to report earnings, which will provide crucial insights into profitability trends and the overall health of the economy.
- Economic Data Focus: Germany, France, and Spain will release inflation data, along with unemployment figures from Germany and France, and UK housing prices, which are likely to influence market sentiment and could trigger trading volatility.
- Political Dynamics Impact: In the UK, the Green Party's victory in the parliamentary by-election in Gorton and Denton has overturned a significant majority for the governing Labour Party, representing a major setback for Prime Minister Keir Starmer and potentially affecting future policy directions.
See More
Puma Biotechnology Q4 2025 Earnings Call Highlights
- Revenue Growth: In Q4 2025, Puma Biotechnology reported total revenue of $75.5 million, with product revenue at $59.9 million, reflecting growth from both the previous quarter and the same quarter last year, indicating stable market performance.
- Surge in Royalty Revenue: Royalty revenue reached $15.6 million in Q4, a significant increase from $2.6 million in Q3, highlighting a substantial rise in shipments to partners in China, which enhances future revenue sustainability.
- Clinical Trial Progress: CEO Auerbach noted that enrollment in the Phase II trials for alisertib in breast cancer and small cell lung cancer has been faster than expected, with 150 patients enrolled by February 2026, and interim data expected in Q2 2026, potentially driving future market opportunities.
- Future Outlook: Puma anticipates net NERLYNX product revenue between $194 million and $198 million for 2026, and despite higher government chargebacks and Medicare share, the company remains optimistic about achieving profitability, demonstrating resilience in financial management.
See More
Puma Biotech (PBYI) Earnings Call Transcript
See More
Puma Biotechnology Q4 Earnings Beat Expectations
- Earnings Highlights: Puma Biotechnology reported a Q4 non-GAAP EPS of $0.29, beating expectations by $0.06, indicating improved profitability and reflecting its competitive position in the biopharmaceutical sector.
- Revenue Growth: Q4 revenue reached $75.5 million, a 27.7% year-over-year increase, surpassing market expectations by $6.9 million, demonstrating sustained demand for its products and driving overall performance.
- 2026 Financial Outlook: The company forecasts Q1 2026 net product revenue between $36 million and $39 million, with total revenue for the year projected at $194 million to $198 million, showcasing confidence in future growth.
- Net Income Projections: For Q1 2026, a net loss is expected between $8 million and $10 million, while the full year could see a net income ranging from $10 million to $13 million, indicating a strategic shift towards profitability.
See More
Adidas Disappoints with 2026 Outlook, Shares Drop
- 2026 Profit Outlook: Adidas forecasts an operating profit of around €2.3 billion ($2.68 billion) for 2026, despite a €400 million negative impact from U.S. tariffs and unfavorable currency fluctuations, which is 15% below overall market expectations, potentially disappointing investors.
- Sales Growth Forecast: The company anticipates high single-digit revenue growth in 2026 based on 2025's total of €24.8 billion ($28.86 billion), indicating that Adidas faces significant challenges in a global sportswear market characterized by excess supply and shifting consumer preferences.
- Stock Price Volatility: Adidas shares fell as much as 8% on Wednesday morning, hitting a fresh 52-week low, and have nearly halved over the past year, reflecting ongoing investor skepticism about the company's future, particularly as it navigates turnarounds alongside competitors Puma and Nike.
- Executive Contract Extension: Adidas also announced the extension of CEO Bjørn Gulden's contract until 2030, signaling confidence in his strategic direction, as Gulden has been working to stabilize the company following its split with rapper Ye, which triggered a significant crisis for the brand.
See More
Adidas Provides Disappointing 2026 Outlook Amidst Challenges
- 2026 Revenue Outlook: Adidas anticipates revenue growth in the high single digits for 2026 from 2025's €24.8 billion ($28.86 billion), despite facing challenges from U.S. tariffs and unfavorable currency fluctuations, indicating vulnerability in a deteriorating market environment.
- Operating Profit Forecast: The company expects operating profit to reach around €2.3 billion, yet a €400 million negative impact from U.S. tariffs results in a profitability outlook that is 15% below market expectations, potentially leading to investor dissatisfaction and declining confidence.
- Sales and Profit Performance: Fourth-quarter sales were €6.1 billion, with profit at €164 million, both slightly missing FactSet estimates, demonstrating that Adidas's growth remains challenged amid external turbulence, which could affect future market performance.
- CEO Contract Extension: Adidas announced the extension of CEO Bjørn Gulden's contract until 2030, reflecting confidence in his strategy, particularly after the split with Ye, as Gulden's leadership is seen as crucial for stabilizing the company.
See More
European Markets Set for Muted Open Ahead of Earnings Reports
- Market Opening Expectations: The London FTSE 100 is projected to open 0.3% higher according to IG data, while Germany's DAX and France's CAC 40 are expected to open nearly flat, indicating a cautious sentiment among investors ahead of upcoming earnings reports and economic data.
- Earnings Reporting Day: On Friday, several European companies including BASF, Swiss Re, Holcim, IAG, and Amadeus are set to report earnings, which will provide crucial insights into profitability trends and the overall health of the economy.
- Economic Data Focus: Germany, France, and Spain will release inflation data, along with unemployment figures from Germany and France, and UK housing prices, which are likely to influence market sentiment and could trigger trading volatility.
- Political Dynamics Impact: In the UK, the Green Party's victory in the parliamentary by-election in Gorton and Denton has overturned a significant majority for the governing Labour Party, representing a major setback for Prime Minister Keir Starmer and potentially affecting future policy directions.
See More
Puma Biotechnology Q4 2025 Earnings Call Highlights
- Revenue Growth: In Q4 2025, Puma Biotechnology reported total revenue of $75.5 million, with product revenue at $59.9 million, reflecting growth from both the previous quarter and the same quarter last year, indicating stable market performance.
- Surge in Royalty Revenue: Royalty revenue reached $15.6 million in Q4, a significant increase from $2.6 million in Q3, highlighting a substantial rise in shipments to partners in China, which enhances future revenue sustainability.
- Clinical Trial Progress: CEO Auerbach noted that enrollment in the Phase II trials for alisertib in breast cancer and small cell lung cancer has been faster than expected, with 150 patients enrolled by February 2026, and interim data expected in Q2 2026, potentially driving future market opportunities.
- Future Outlook: Puma anticipates net NERLYNX product revenue between $194 million and $198 million for 2026, and despite higher government chargebacks and Medicare share, the company remains optimistic about achieving profitability, demonstrating resilience in financial management.
See More
Puma Biotech (PBYI) Earnings Call Transcript
See More
Puma Biotechnology Q4 Earnings Beat Expectations
- Earnings Highlights: Puma Biotechnology reported a Q4 non-GAAP EPS of $0.29, beating expectations by $0.06, indicating improved profitability and reflecting its competitive position in the biopharmaceutical sector.
- Revenue Growth: Q4 revenue reached $75.5 million, a 27.7% year-over-year increase, surpassing market expectations by $6.9 million, demonstrating sustained demand for its products and driving overall performance.
- 2026 Financial Outlook: The company forecasts Q1 2026 net product revenue between $36 million and $39 million, with total revenue for the year projected at $194 million to $198 million, showcasing confidence in future growth.
- Net Income Projections: For Q1 2026, a net loss is expected between $8 million and $10 million, while the full year could see a net income ranging from $10 million to $13 million, indicating a strategic shift towards profitability.
See More
